The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses

References

• Saiz JC, Vázquez-Calvo Á, Blázquez AB, et al. Zika virus: the latest newcomer. Front Microbiol. 2016;7:496.
   PubMed Web of Science ®Google Scholar
• Pielnaa P, Al-Saadawe M, Saro A, et al. Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology. 2020;543:34–42.
   Web of Science ®Google Scholar
• Agarwal A, Chaurasia D. The expanding arms of Zika virus: an updated review with recent Indian outbreaks. Rev Med Virol. 2021;31(1):1–9.
   PubMed Web of Science ®Google Scholar
• Ryan SJ, Carlson CJ, Tesla B, et al. Warming temperatures could expose more than 1.3 billion new people to Zika virus risk by 2050. Glob Chang Biol. 2021;27(1):84–93.
   Web of Science ®Google Scholar
• Dowd KA, Ko S-Y, Morabito KM, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016;354(6309):237–240.
   PubMed Web of Science ®Google Scholar
• Pattnaik A, Sahoo BR, Pattnaik AK. Current status of Zika virus vaccines: successes and challenges. Vaccines. 2020;8(2):266.
   Web of Science ®Google Scholar
• García-Arriaza J, Garaigorta U, Pérez P, et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J Virol. 2021;95(7):e02260–20.
   Google Scholar
• Gómez CE, Nájera JL, Perdiguero B, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol. 2011;85(21):11468–11478.
   PubMed Web of Science ®Google Scholar
• Volz A, Sutter G. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv Virus Res. 2017;97:187–243.
   PubMed Web of Science ®Google Scholar
• Price PJR, Torres-Domínguez LE, Brandmüller C, et al. Modified vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine. 2013;31(39):4231–4234.
   PubMed Web of Science ®Google Scholar
• Delaloye J, Roger T, Steiner-Tardivel Q-G, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 2009;5(6):e1000480.
   PubMed Web of Science ®Google Scholar
• Pérez P, Marín MQ, Lázaro-Frías A, et al. A vaccine based on a modified vaccinia virus Ankara vector expressing Zika virus structural proteins controls Zika virus replication in mice. Sci Rep. 2018;8(1):17385.
   Google Scholar
• Yang Z-y, Wyatt LS, Kong W-p, et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2003;77(1):799–803.
   PubMed Web of Science ®Google Scholar
• Li S, Rodrigues M, Rodriguez D, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA. 1993;90(11):5214–5218.
   PubMed Web of Science ®Google Scholar
• Marín MQ, Pérez P, Ljungberg K, et al. Potent anti-hepatitis C virus (HCV) T cell immune responses induced in mice vaccinated with DNA-launched RNA replicons and modified vaccinia virus Ankara-HCV. J Virol. 2019;93(7):e00055–19.
   Web of Science ®Google Scholar
• Lorenzo G, López-Gil E, Ortego J, et al. Efficacy of different DNA and MVA prime-boost vaccination regimens against a rift valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination. Vet Res. 2018;49(1):21.
   Google Scholar
• Gray GE, Mayer KH, Elizaga ML, et al. Subtype C gp140 vaccine boosts immune responses primed by the South African AIDS vaccine initiative DNA-C2 and MVA-C HIV vaccines after more than a 2-year Gap. Clin Vaccine Immunol. 2016;23(6):496–506.
   Google Scholar
• Joachim A, Bauer A, Joseph S, et al. Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: A phase I trial. PLoS One. 2016;11(5):e0155702.
   PubMed Web of Science ®Google Scholar
• Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6(261):261ra153.
   PubMed Web of Science ®Google Scholar
• Mensah VA, Gueye A, Ndiaye M, et al. Safety, immunogenicity and efficacy of prime-boost vaccination with ChAd63 and MVA encoding ME-TRAP against plasmodium falciparum infection in adults in Senegal. PLoS One. 2016;11(12):e0167951.
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Venkatraman N, et al. A monovalent Chimpanzee Adenovirus ebola vaccine boosted with MVA. N Engl J Med. 2016;374(17):1635–1646.
   PubMed Web of Science ®Google Scholar
• Green CA, Scarselli E, Sande CJ, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015;7(300):300ra126.
   PubMed Web of Science ®Google Scholar
• Li Y, Bi Y, Xiao H, et al. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2021;10(1):342–355.
   PubMed Web of Science ®Google Scholar
• He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629–637.
   PubMed Web of Science ®Google Scholar
• Vázquez-Calvo Á, Blázquez A-B, Escribano-Romero E, et al. Zika virus infection confers protection against West Nile virus challenge in mice. Emerg Microbes Infect. 2017;6:e81.
   PubMed Web of Science ®Google Scholar
• Blázquez AB, Escribano-Romero E, Merino-Ramos T, et al. Infection with Usutu virus induces an autophagic response in mammalian cells. PLoS Negl Trop Dis. 2013;7:e2509.
   Web of Science ®Google Scholar
• Merino-Ramos T, Blázquez A-B, Escribano-Romero E, et al. Protection of a single dose West Nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus. PLoS One. 2014;9:e108056.
   PubMed Web of Science ®Google Scholar
• Martin-Acebes MA, Merino-Ramos T, Blazquez A-B, et al. The composition of West Nile virus lipid envelope unveils a role of sphingolipid metabolism in flavivirus biogenesis. J Virol. 2014;88(20):12041–12054.
   Web of Science ®Google Scholar
• García-Arriaza J, Nájera JL, Gómez CE, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One. 2011;6(8):e24244.
   PubMed Web of Science ®Google Scholar
• García-Arriaza J, Arnáez P, Gómez CE, et al. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by Deletion of vaccinia virus genes (C6L and K7R) blocking Interferon signaling pathways. PLoS One. 2013;8(6):e66894.
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Gomez CE, Sorzano COS, et al. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol. 2014;88:3392–3410.
   PubMed Web of Science ®Google Scholar
• Pérez P, Marín MQ, Lázaro-Frías A, et al. An MVA vector expressing HIV-1 envelope under the control of a potent vaccinia virus promoter as a promising strategy in HIV/AIDS vaccine design. Vaccines. 2019;7:208.
   Web of Science ®Google Scholar
• Perdiguero B, Gómez CE, García-Arriaza J, et al. Heterologous combination of VSV-GP and NYVAC vectors expressing HIV-1 trimeric gp145 Env as vaccination strategy to induce balanced B and T cell immune responses. Front Immunol. 2019;10:2941.
   Web of Science ®Google Scholar
• Perdiguero B, Raman SC, Sánchez-Corzo C, et al. Potent HIV-1-specific CD8 T cell responses induced in mice after priming with a multiepitopic DNA-TMEP and boosting with the HIV vaccine MVA-B. Viruses. 2018;10(8):424.
   Web of Science ®Google Scholar
• García-Arriaza J, Nájera JL, Gómez CE, et al. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One. 2010;5(8):e12395.
   PubMed Web of Science ®Google Scholar
• Lorenz IC, Kartenbeck J, Mezzacasa A, et al. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol. 2003;77(7):4370–4382.
   Web of Science ®Google Scholar
• Wen J, Elong Ngono A, Angel Regla-Nava J, et al. Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge. Nat Commun. 2017;8(1):1459.
   PubMedGoogle Scholar
• Nazerai L, Schøller AS, Bassi MR, et al. Effector CD8 T cell-dependent Zika virus control in the CNS: a matter of time and numbers. Front Immunol. 2020;11:1977.
   Web of Science ®Google Scholar
• Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529–542.
   PubMed Web of Science ®Google Scholar
• Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol. 2009;10(4):385–393.
   PubMed Web of Science ®Google Scholar
• Larocca RA, Abbink P, Peron JPS, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536(7617):474–478.
   PubMed Web of Science ®Google Scholar
• Abbink P, Larocca RA, De La Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353(6304):1129–1132.
   PubMed Web of Science ®Google Scholar
• Betancourt D, de Queiroz NMGP, Xia T, et al. Cutting edge: Innate immune augmenting vesicular stomatitis virus expressing Zika virus proteins confers protective immunity. J Immunol. 2017;198(8):3023–3028.
   PubMed Web of Science ®Google Scholar
• Nürnberger C, Bodmer BS, Fiedler AH, et al. A measles virus-based vaccine candidate mediates protection against Zika virus in an allogeneic mouse pregnancy model. J Virol. 2019;93(3):e01485–18.
   Web of Science ®Google Scholar
• Zhan Y, Deng Y, Huang B, et al. Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine. 2019;37(15):2122–2130.
   Web of Science ®Google Scholar
• López-Camacho C, Kim YC, Abbink P, et al. Assessment of immunogenicity and efficacy of a zika vaccine using modified vaccinia Ankara virus as carriers. Pathogens. 2019;8(4):216.
   Web of Science ®Google Scholar
• Prow NA, Liu L, Nakayama E, et al. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. Nat Commun. 2018;9(1):1230.
   PubMedGoogle Scholar
• Brault AC, Domi A, McDonald EM, et al. A Zika vaccine targeting NS1 protein protects immunocompetent adult mice in a lethal challenge model. Sci Rep. 2017;7(1):14769.
   PubMed Web of Science ®Google Scholar
• Ngono AE, Shresta S. Immune response to Dengue and Zika. Annu Rev Immunol. 2018;36:279–308.
   PubMed Web of Science ®Google Scholar
• Yau C, Gan ES, Kwek SS, et al. Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection. EBioMedicine. 2020;61:103028.
   PubMed Web of Science ®Google Scholar
• Pardy RD, Richer MJ. Protective to a T: the role of T cells during Zika virus infection. Cells. 2019;8(8):820.
   Web of Science ®Google Scholar
• Gaudinski MR, Houser KV, Morabito KM, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018;391(10120):552–562.
   PubMed Web of Science ®Google Scholar
• Steffen T, Hassert M, Hoft SG, et al. Immunogenicity and efficacy of a recombinant human adenovirus type 5 vaccine against Zika virus. Vaccines. 2020;8(2):170.
   Web of Science ®Google Scholar
• Hassert M, Harris MG, Brien JD, et al. Identification of protective CD8 T cell responses in a mouse model of Zika virus infection. Front Immunol. 2019;10:1678.
   PubMed Web of Science ®Google Scholar
• Guo Q, Chan JF-W, Poon VK-M, et al. Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models. J Infect Dis. 2018;218(3):365–377.
   PubMed Web of Science ®Google Scholar
• Bullard BL, Corder BN, Gorman MJ, et al. Efficacy of a T cell-biased Adenovirus vector as a Zika virus vaccine. Sci Rep. 2018;8(1):18017.
   Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–258.
   PubMed Web of Science ®Google Scholar
• Samy N, Reichhardt D, Schmidt D, et al. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase I clinical trial. Vaccine. 2020;38(11):2608–2619.
   PubMed Web of Science ®Google Scholar
• García F, Bernaldo de Quirós JCL, Gómez CE, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011;29(46):8309–8316.
   PubMed Web of Science ®Google Scholar
• Tebas P, Roberts CC, Muthumani K, et al. Safety and immunogenicity of an anti–Zika virus DNA vaccine – preliminary report. N Engl J Med. 2017. doi:https://doi.org/10.1056/NEJMoa1708120.
   Google Scholar